Shiga Toxin–Induced Complement-Mediated Hemolysis and Release of Complement-Coated Red Blood Cell–Derived Microvesicles in Hemolytic Uremic Syndrome

Shiga toxin (Stx)-producing Escherichia coli (STEC) cause hemolytic uremic syndrome (HUS). This study investigated whether Stx2 induces hemolysis and whether complement is involved in the hemolytic process. RBCs and/or RBC-derived microvesicles from patients with STEC-HUS (n = 25) were investigated for the presence of C3 and C9 by flow cytometry. Patients exhibited increased C3 deposition on RBCs compared with controls (p < 0.001), as well as high levels of C3- and C9-bearing RBC-derived microvesicles during the acute phase, which decreased after recovery. Stx2 bound to P1k and P2k phenotype RBCs, expressing high levels of the Pk Ag (globotriaosylceramide), the known Stx receptor. Stx2 induced the release of hemoglobin and lactate dehydrogenase in whole blood, indicating hemolysis. Stx2-induced hemolysis was not demonstrated in the absence of plasma and was inhibited by heat inactivation, as well as by the terminal complement pathway Ab eculizumab, the purinergic P2 receptor antagonist suramin, and EDTA. In the presence of whole blood or plasma/serum, Stx2 induced the release of RBC-derived microvesicles coated with C5b-9, a process that was inhibited by EDTA, in the absence of factor B, and by purinergic P2 receptor antagonists. Thus, complement-coated RBC-derived microvesicles are elevated in HUS patients and induced in vitro by incubation of RBCs with Stx2, which also induced hemolysis. The role of complement in Stx2-mediated hemolysis was demonstrated by its occurrence only in the presence of plasma and its abrogation by heat inactivation, EDTA, and eculizumab. Complement activation on RBCs could play a role in the hemolytic process occurring during STEC-HUS.

[1]  T. Vorup-Jensen,et al.  Leukotoxin from Aggregatibacter actinomycetemcomitans causes shrinkage and P2X receptor‐dependent lysis of human erythrocytes , 2012, Cellular microbiology.

[2]  H. Praetorius,et al.  P2X receptor stimulation amplifies complement-induced haemolysis , 2012, Pflügers Archiv - European Journal of Physiology.

[3]  D. Karpman.  Management of Shiga toxin-associated Escherichia coli-induced haemolytic uraemic syndrome: randomized clinical trials are needed , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  Ulrich C. Klostermeier,et al.  Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104:H4 induced haemolytic uraemic syndrome: case-control study , 2012, BMJ : British Medical Journal.

[5]  M. Rundgren,et al.  [The HUS epidemic in the summer of 2011 was severe. German and Swedish experiences of the EHEC outbreak]. , 2012, Lakartidningen.

[6]  R. Furlan,et al.  Microglial Microvesicle Secretion and Intercellular Signaling , 2012, Front. Physio..

[7]  E. Flores-Soto,et al.  PPADS, a P2X receptor antagonist, as a novel inhibitor of the reverse mode of the Na⁺/Ca²⁺ exchanger in guinea pig airway smooth muscle. , 2012, European journal of pharmacology.

[8]  A. Mellmann,et al.  Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: a microbiological study. , 2011, The Lancet. Infectious diseases.

[9]  H. Praetorius,et al.  Haemolysis induced by α-toxin from Staphylococcus aureus requires P2X receptor activation , 2011, Pflügers Archiv - European Journal of Physiology.

[10]  G. Remuzzi,et al.  Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis , 2011, The Journal of Immunology.

[11]  A. Edefonti,et al.  Clinical Relevance of Shiga Toxin Concentrations in the Blood of Patients With Hemolytic Uremic Syndrome , 2011, The Pediatric infectious disease journal.

[12]  D. Karpman,et al.  Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome. , 2011, Blood.

[13]  J. S. Westman,et al.  Identification of a novel A4GALT exon reveals the genetic basis of the P1/P2 histo-blood groups. , 2011, Blood.

[14]  J. Tissot,et al.  Analysis and clinical relevance of microparticles from red blood cells , 2010, Current opinion in hematology.

[15]  N. Lion,et al.  Pre-analytical and methodological challenges in red blood cell microparticle proteomics. , 2010, Talanta.

[16]  N. Lion,et al.  Microparticles in stored red blood cells: submicron clotting bombs? , 2010, Blood transfusion = Trasfusione del sangue.

[17]  U. Jensen,et al.  Escherichia coli α-Hemolysin Triggers Shrinkage of Erythrocytes via KCa3.1 and TMEM16A Channels with Subsequent Phosphatidylserine Exposure* , 2010, The Journal of Biological Chemistry.

[18]  J. Thurman,et al.  Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. , 2009, Clinical journal of the American Society of Nephrology : CJASN.

[19]  D. Karpman,et al.  Shiga Toxin and Lipopolysaccharide Induce Platelet-Leukocyte Aggregates and Tissue Factor Release, a Thrombotic Mechanism in Hemolytic Uremic Syndrome , 2009, PloS one.

[20]  P. Zipfel,et al.  Complement regulators and inhibitory proteins , 2009, Nature Reviews Immunology.

[21]  N. Jørgensen,et al.  α-Hemolysin from Escherichia coli uses endogenous amplification through P2X receptor activation to induce hemolysis , 2009, Proceedings of the National Academy of Sciences.

[22]  B. Lentz,et al.  A phosphatidylserine binding site in factor Va C1 domain regulates both assembly and activity of the prothrombinase complex. , 2008, Blood.

[23]  F. Di Virgilio,et al.  Stimulation of P2 receptors causes release of IL-1beta-loaded microvesicles from human dendritic cells. , 2007, Blood.

[24]  G. Remuzzi,et al.  A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. , 2006, Kidney international.

[25]  A. Edefonti,et al.  Shiga Toxins Present in the Gut and in the Polymorphonuclear Leukocytes Circulating in the Blood of Children with Hemolytic-Uremic Syndrome , 2006, Journal of Clinical Microbiology.

[26]  P. Tarr,et al.  Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome , 2005, The Lancet.

[27]  K. Yazdanbakhsh.  Controlling the complement system for prevention of red cell destruction , 2005, Current opinion in hematology.

[28]  D. Erlinge,et al.  ADP Acting on P2Y13 Receptors Is a Negative Feedback Pathway for ATP Release From Human Red Blood Cells , 2005, Circulation research.

[29]  D. Crossman,et al.  Secretion of Intracellular IL-1 Receptor Antagonist (Type 1) Is Dependent on P2X7 Receptor Activation1 , 2004, The Journal of Immunology.

[30]  B. Matkovics,et al.  Oxidative damage of red blood cells in haemolytic uraemic syndrome , 1994, Pediatric Nephrology.

[31]  Role of procoagulant lipids in human prothrombin activation. 2. Soluble phosphatidylserine upregulates and directs factor X(a) to appropriate peptide bonds in prothrombin. , 2002, Biochemistry.

[32]  B. Lentz,et al.  Role of procoagulant lipids in human prothrombin activation. 1. Prothrombin activation by factor X(a) in the absence of factor V(a) and in the absence and presence of membranes. , 2002, Biochemistry.

[33]  G. Remuzzi,et al.  Thrombotic microangiopathy, hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: Rare manifestations of Russell’s viper (Daboia russelii) envenoming in Sri Lanka , 2021 .

[34]  V. V. van Hinsbergh,et al.  Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. , 2000, Blood.

[35]  A. Weintraub,et al.  Enteropathogens in adult patients with diarrhea and healthy control subjects: a 1-year prospective study in a Swedish clinic for infectious diseases. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  P. Spitalnik,et al.  The P blood group system: biochemical, serological, and clinical aspects. , 1995, Transfusion medicine reviews.

[37]  M. Petric,et al.  Evidence that verotoxins (Shiga-like toxins) from Escherichia coli bind to P blood group antigens of human erythrocytes in vitro , 1994, Infection and immunity.

[38]  Y. Yawata.  [Hemolytic anemia]. , 1994, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine.

[39]  G. Fick,et al.  Hypocomplementemia and leukocytosis in diarrhea-associated hemolytic uremic syndrome. , 1992, Nephron.

[40]  J. Brown,et al.  Identification of the carbohydrate receptor for Shiga toxin produced by Shigella dysenteriae type 1. , 1987, The Journal of biological chemistry.

[41]  P. Lambert,et al.  The complement system in hemolytic-uremic syndrome in childhood. , 1980, Clinical nephrology.

[42]  R. Good,et al.  Suramin--a potent reversible and competitive inhibitor of complement systems. , 1972, Clinical and experimental immunology.

[43]  T. H. Ham,et al.  STUDIES ON DESTRUCTION OF RED BLOOD CELLS. II. CHRONIC HEMOLYTIC ANEMIA WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: CERTAIN IMMUNOLOGICAL ASPECTS OF THE HEMOLYTIC MECHANISM WITH SPECIAL REFERENCE TO SERUM COMPLEMENT. , 1939, The Journal of clinical investigation.

[44]  P. Strübing.  Paroxysmale Haemoglobinurie (Fortsetzung und Schluss) , 1882 .